In collaboration with

Endpoints News is the biopharma and healthcare industries' trusted source for up-to-the-moment news, in-depth reporting on science and business, and coverage of the people, companies and money that drive innovation. 

Endpoints readers are decision-makers, executives, drug developers, business development leaders, investors and regulators who need to know everything that’s happening in biotech and pharma. More than 190,000 specialists get Endpoints’ newsletters every day, including at every major pharmaceutical manufacturer and at hundreds of biotechnology companies, service providers and startups. 

Global Clinical Research Partner

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life. ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs. With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees

Innovation Partner

Cognizant (Nasdaq-100: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant.

Knowledge Partner

Whether you’re looking to find greater value and efficiencies, or entirely reinvent your business model, we combine industry expertise with technology capabilities to help you unlock your potential with AI. With 175 years’ experience managing disruption, 5,000 technologists and 15,000 of our UK people set up with GenAI tools and skills, we can tailor a response to any challenge. 

From enhancing drug discovery and streamlining operations, to improving patient outcomes, and more, we work with organisations across the pharmaceutical value chain to realise the growth opportunities emerging technologies present. 

Discover our human-led, tech-powered approach to transformation. 

Visit PwC.co.uk to unlock your potential for AI

Lead Sponsor

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.

Lead Sponsor

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.janssen.com/emea/.

Lead Sponsor

 Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma,non-small cell lung cancer and pancreatic cancer.

Lead Sponsor

Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. 

We focus on finding new medicines and diagnostics and establishing data-based insights that evolve the practice of medicine and help patients live longer, better lives.

Associate Sponsor

A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets. This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world.

Associate Sponsor

IBM is a leading global hybrid cloud & AI and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. 

IBM Consulting is working with global clients and partners to co-create what’s next in AI. With a deep understanding of emerging trends and industry disruptions, our teams are building industry-based solutions to real-world problems. We will uncover untapped potential inside your business and help deliver new levels of productivity and growth. 

Our IBM Consulting services help you align your team around a vision, activate your data and right size roadmaps and technology investments. Our co-creative, human-centric approach helps you realize additional value from existing and emerging technologies, improve decision-making and problem solving to increase competitive advantage and long-term sustainable impact. For more information, visit www.ibm.com/consulting

We have a few packages remaining, get in touch today to see how you can get involved.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice